SynthesisInternational journal of clinical oncology2024

Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.

Toshinobu Hayashi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.